In this slideshow, we highlight some of the most innovative and important clinical advances in the treatment of atopic dermatitis.
Dermatology Times Staff
In this slideshow, we highlight some of this year's clinical advances in psoriasis and plaque psoriasis.
The FDA is exploring ways to prevent long-term drug shortages and allow more drug importation so patients have access to medically necessary drugs.
Physicians throughout the country are recruiting patients for two phase three clinical trials of cantharidin for the treatment of molluscum contagiousum. a viral skin condition.
Ortho Dermatologics announced in August that it resubmitted a new drug application to the FDA for DUOBRIITM1, a lotion for the treatment of plaque psoriasis.
PharmaTimes reported in August that the Spanish company Almirall acquired Allergan’s U.S. dermatology portfolio for $650 million.
In October, the Food and Drug Administratin is expected to decide on the approval of omadacycline (Paratek Pharmaceuticals) for the treatment of acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.
88 percent of the U.S. population has regular access to healthcare, shows an analysis by WalletHub which in August released its 2018 Best and Worst States for Health Care list.
The European Academy of Dermatology and Venerology (EADV) 2018 meeting takes this week in Paris. Visit our EADV conference news site to follow the developments from Paris.